Modified Citrus Pectin for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

Modified Citrus Pectin for Health & Longevity

Created on 10/20/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

Modified citrus pectin, a dietary supplement of citrus-peel fiber cut into small fragments, is promoted to block a protein linked to tissue scarring and cancer spread. Animal and laboratory studies are encouraging, but in people, studies without comparison groups report slower rises in a prostate cancer blood marker and more urinary loss of toxic metals, while the few trials against placebo found no benefit. Risks appear modest, mainly digestive complaints. (Full Review)

Protocol

Standard trial dose
14.4 g/day
PectaSol-C 4.8 g three times daily for 6–18 months; trials used 8–15 g/day
Single or split dosing
Three split doses
Used in most trials; also eases digestive tolerance
Time of day
No preferred time established
One trial: half an hour before or 2 hours after food
Time to effect
PSA doubling time
6 months
Point at which PSA trends were judged in the prostate trial
Urinary metal changes
1–6 days
Increased urinary excretion of toxic metals

Benefits

Contraindications
  • People with known pectin or citrus allergy
  • People with cashew or pistachio allergy (caution)
  • People with eGFR below 45 mL/min/1.73 m² or potassium above 5.2 on screening
  • Pregnant or breastfeeding women
  • People with cancer considering it in place of standard treatment
    •
Key Interactions
  • Digoxin: Caution
  • Statins (cholesterol-lowering drugs: lovastatin, simvastatin): Caution
  • Narrow-margin oral drugs (levothyroxine, warfarin): Monitor (theoretical)
  • Acetaminophen (paracetamol, over the counter): Minor
  • Antidiarrheals and laxatives (loperamide, bisacodyl): Monitor (theoretical)
  • Potassium-raising drugs (lisinopril, spironolactone, potassium supplements): Monitor (theoretical)
  • Chemotherapy and radiotherapy (paclitaxel, doxorubicin): Caution (theoretical)
  • Carotenoid and vitamin E supplements (beta-carotene, lutein, alpha-tocopherol): Caution
  • Mineral supplements (iron, zinc, calcium): Monitor
  • Other fibers and alginate (psyllium, sodium alginate): Monitor (theoretical)
  • Chelation therapy (metal-binding drugs: DMSA/succimer, EDTA/edetate): Caution (theoretical)
    •

Risk & Side Effects

  • High:
  • Medium: Conflicted: digestive intolerance
    •
  • Low: Allergic and skin reactions, high blood potassium; conflicted: reduced absorption of co-ingested nutrients and drugs
    •
  • Speculative: Interference with galectin-3's normal roles, delay of effective cancer treatment
    •

Monitoring

Marker Target Why
Serum potassium 3.5–5.0 mmol/L Safety check: rise would pause use
eGFR / serum creatinine Serum creatinine about 0.6–1.3 mg/dL; eGFR >59 mL/min/1.73 m²; track change from own baseline Safety check: decline would stop use
PSA and PSA doubling time (men with prostate cancer) PSA 0.0–4.0 ng/mL; track doubling time against own pre-treatment trend Expected to change: main outcome in prostate trials
Blood lead (if used for metal exposure) 0.0–3.4 µg/dL; track change from own baseline Expected to change: outcome in metal-excretion studies

Cadence: Baseline, week 6, then every 3–6 months for potassium and kidney function; PSA every 3 months in men with prostate cancer; blood lead after 4 weeks of a metal-focused course

Qualitative Assessment

  • Digestive tolerance: bloating, gas and stool pattern
  • New itching or skin reactions
  • Energy, appetite and quality of life
  • Joint pain and stiffness, where osteoarthritis motivates use
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.